{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:14:05Z","timestamp":1777515245420,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Celgene Canada"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Qu\u00e9bec, targeted biologic therapies for moderate to severe plaque psoriasis are restricted to patients who have not responded to phototherapy or conventional systemic treatment, primarily due to high drug costs. Apremilast, an oral treatment for plaque psoriasis, was added to the Qu\u00e9bec provincial health insurance plan (R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec; RAMQ) formulary in 2015, making this the only province in Canada with public drug plan reimbursement for apremilast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study is to describe patients\u2019 characteristics, treatment patterns, healthcare resource utilization (HCRU), and associated costs and to measure real-world budget impact of using apremilast before biologics in plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was performed using RAMQ drug claims and medical services data. Patients diagnosed with psoriasis between January 2015 and December 2017 were identified. Medical services and prescription claims were categorized as all-cause and psoriasis-related. Using RAMQ database estimates, a 3-year budget impact analysis was developed comparing treatment cost with and without the addition of apremilast to the formulary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all, 540 patients were identified (apremilast: n = 92; biologics: n = 448). Comorbidity burden and treatment persistence and adherence were comparable between apremilast and biologic users. The year following the index date, all-cause HCRU was lower for apremilast versus biologic users (CAN$19 763 vs CAN$28 025; P &lt; .01), mainly driven by drug cost. Using apremilast before biologics resulted in an estimated RAMQ net savings of CAN$49 290 (2015), CAN$746 856 (2016), and CAN$1 216 512 (2017), and a total savings of CAN$2 012 658 since apremilast\u2019s addition to the formulary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding apremilast to the drug formulary of other Canadian provinces could result in significant healthcare savings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1203475420936652","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:38:47Z","timestamp":1593430727000},"page":"573-587","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Qu\u00e9bec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-0870","authenticated-orcid":false,"given":"Yves","family":"Poulin","sequence":"first","affiliation":[{"name":"Centre Dermatologique du Qu\u00e9bec M\u00e9tropolitain, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Beauchemin","sequence":"additional","affiliation":[{"name":"H\u00f4pital H\u00f4tel-Dieu de Qu\u00e9bec and Pharmacoeconomics and Outcomes Research, PeriPharm Inc., Montr\u00e9al, Canada"},{"name":"Faculty of Pharmacy, University of Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Royer","sequence":"additional","affiliation":[{"name":"H\u00f4pital H\u00f4tel-Dieu de Qu\u00e9bec and Pharmacoeconomics and Outcomes Research, PeriPharm Inc., Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Julie","family":"Gaudreau","sequence":"additional","affiliation":[{"name":"Medical Affairs, Amgen Canada Inc., Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarabella","family":"Yim","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Celgene Inc., Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Celgene Inc., Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-2518","authenticated-orcid":false,"given":"Jean","family":"Lachaine","sequence":"additional","affiliation":[{"name":"H\u00f4pital H\u00f4tel-Dieu de Qu\u00e9bec and Pharmacoeconomics and Outcomes Research, PeriPharm Inc., Montr\u00e9al, Canada"},{"name":"Faculty of Pharmacy, University of Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"bibr1-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"bibr2-1203475420936652","volume-title":"List of medications","author":"R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec","year":"2019"},{"key":"bibr3-1203475420936652","unstructured":"R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec. [Annual management report 2016-2017]. Regie de l'assurance maladie du Quebec. Accessed March 7, 2019. http:\/\/www.ramq.gouv.qc.ca\/SiteCollectionDocuments\/citoyens\/fr\/rapports\/rappann1617.pdf"},{"key":"bibr4-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00234-H"},{"key":"bibr5-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"bibr6-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1177\/2045125318782694"},{"key":"bibr7-1203475420936652","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826060-00003"},{"key":"bibr8-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12267"},{"key":"bibr9-1203475420936652","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S108115"},{"key":"bibr10-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"bibr11-1203475420936652","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12549"},{"key":"bibr12-1203475420936652","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0097"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475420936652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475420936652","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475420936652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:54:36Z","timestamp":1777391676000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475420936652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1177\/1203475420936652"],"URL":"https:\/\/doi.org\/10.1177\/1203475420936652","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]}}}